AVF-BSCI Translational Research Grant
- Nonthrombotic venous obstruction
- Venous thromboembolism
- Superficial venous insufficiency
- Human subject requirement: Patient-oriented research involving human subjects or with tissue of human origin
- Address delivery of appropriate care to appropriate patients and/or translate new clinical data into clinical decision making
- Residents and fellows in a training program
- Physicians who have completed their training within the past ten (10) years
- Applicants who have not previously received this award
- The 2023 AVF-BSCI Translational Research Grant will accept submissions from International as well as US-based researchers
The grant will provide funding for direct research-related costs and travel expenses to attend the annual AVF meeting to accept the award and provide annual progress reports on the study. The awardee will be required to provide a progress update and budget report every 6 months. The grant award WILL NOT pay for indirect costs to the researcher’s university or facility.
- The AVF-BSCI Translational Research Grant will be awarded to an original, translational research project in venous disease addressing venous obstruction with an emphasis on the treatment of appropriate patients with appropriate care, venous thrombus management with an emphasis on understanding morphology, or the management and treatment of superficial venous insufficiency.
- Applicants must be a resident or fellow in a training program located in the United States or a physician who has completed their training within the past ten (10) years, have not previously received this award and are currently based in the United States.
- Either the applicant or their mentor must be an AVF Member at the time of submission. The awardee is expected to join the AVF and maintain their membership for the duration of the grant period.
- The applicant’s mentor and institution must also be located in the United States.
- A no-cost extension will be permitted to allow for variability in research progression on a case-by-case basis only, upon written request by the applicant, and will require approval from the Research Committee, Research Council Chair, and Board of Directors.
- All residents and fellows are required to include a letter from the Program Director confirming a two-year commitment to the project and enough time dedicated to research during this period.
- The applicant must attest, in their cover letter, that they are not currently excluded by the Office of the Inspector General from participation in Medicare, Medicaid, or other Federal health care programs.
- The awardee’s institution must provide a signed W-9 prior to the initial disbursement. Subsequent requests for disbursement must be accompanied by a formal letter of request for funding, an itemized invoice correlating to the originally submitted budget, and an update on the status of the research project. The Research Committee will review these requests prior to approving the disbursement.
- The awardee is required to attend the AVF Annual Meeting to receive the award as well as the subsequent two Annual Meeting to provide a YEAR 1 preliminary report on the grant project and YEAR 2 final report on the grant project. This requirement is mandatory.
- During the first 12 months of the grant award, the awardee agrees to visit Boston Scientific’s corporate headquarters and manufacturing facility. Expenses for this visit are not included in the grant award and will be reimbursed separately by BSCI. This requirement is mandatory.
Applicants must submit the following in PDF format via the online submission process:
- A completed Application (PDF)
- A completed Application (Word)
- The applicant’s curriculum vitae
- The mentor’s curriculum vitae
- A letter of support from the sponsor (mentor) of the project including verification of resources available to support the project
- If neither the applicant nor their mentor is an AVF member, the applicant must submit an application for membership prior to submitting their grant application
- Submission deadline: Monday, August 15, 2022